192124-88-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dichloro-6-Nitrobenzyl Chloride is used as a chemical intermediate for the synthesis of Anagrelide (A637300), a phosphodiesterase inhibitor with antiplatelet activity. Anagrelide serves as an antithrombocythemic, which helps in managing thrombocytosis by reducing the production of platelets in the bone marrow.
Additionally, 2,3-Dichloro-6-Nitrobenzyl Chloride may be used as an impurity reference substance in the quality control and analysis of Anagrelide, ensuring the purity and safety of the final pharmaceutical product. This application is crucial for maintaining the efficacy and reliability of Anagrelide as a therapeutic agent in the treatment of thrombocytosis and related conditions.

Downstream Products

• 70380-50-6 N-(2,3-dichloro-6-nitrobenzyl)glycine ethyl ester hydrochloride 
• 70380-49-3 2,3-dichloro-6-nitrobenzylamine 
• 85061-55-8 2-Amino-1-(2,3-dichloro-6-nitro-benzyl)-1,5-dihydro-imidazol-4-one; hydrochloride 
• 85325-11-7 (2,3-Dichloro-6-nitro-benzylamino)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Method for the manufacture of anagrelide

Methods are provided for making Anagrelide base from 2,3-dichlorobenzaldehyde. A method is also provided for making an intermediate compound ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde and for reducing the glycine compound using either SnCl2 or a specially defined catalyst. A cyclization method to form Anagrelide base from the corresponding iminoquinazoline compound is further provided.

2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

The compound 2-amino-5,6-dichloro-3,4-dihydroquinazoline has been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compound and a method of reducing the platelet count in a patient by administering to the patient a platelet reducing effective amount of the compound preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains the above compound as the active ingredient together with pharmaceutically acceptable excipients.